新冠肺炎住院患者继续与停用肾素-血管紧张素系统抑制剂:前瞻性随机开放标签试验
REPLACE COVID trial为前瞻性、随机、开放标签试验,在7国20家大型转诊医院纳入152例既往使用RAS抑制剂的COVID-19住院患者,1:1随机分为继续或停用RAS抑制剂。主要终点为全球排名评分(整合死亡时间、机械通气时间、肾脏替代或血管加压药治疗时间及住院期间多器官功能障碍),继续组与停药组无差异(中位排名73 vs 81,β系数8,95%CI -13至29)。两组ICU入住或有创机械通气率、病死率及不良事件无显著差异。结论支持COVID-19住院患者可安全继续RAS抑制剂。
要点
- REPLACE COVID trial纳入152例既往使用RAS抑制剂的COVID-19住院患者,继续与停用RAS抑制剂主要终点无差异(β系数8,95%CI -13至29)。
- 继续组与停药组ICU入住或有创机械通气率分别为21% vs 18%,病死率分别为15% vs 13%,均无显著差异。
- 对于COVID-19住院且既往使用RAS抑制剂的患者,继续用药不增加风险,可安全继续。
- 该试验样本量小(152例),主要终点为复合排名评分,需结合个体情况评估。
适用人群与场景
- 年龄≥18岁、因COVID-19住院且入院前正在使用肾素-血管紧张素系统抑制剂(ACEI或ARB)的患者。
- 排除对继续或停用RAS抑制剂有禁忌的患者。
- 研究场景为7国20家大型转诊医院的住院患者。
诊断标准与关键阈值
- 主要终点为全球排名评分,整合四个层级:死亡时间、机械通气持续时间、肾脏替代或血管加压药治疗时间、住院期间多器官功能障碍。
- 原文未提及具体的诊断界值或启动/停止阈值。
处置流程与药物剂量
- 第一步:确认患者因COVID-19住院且入院前正在使用RAS抑制剂(ACEI或ARB)。
- 第二步:评估有无继续或停用RAS抑制剂的禁忌证。
- 第三步:无禁忌者可继续使用原RAS抑制剂,无需停药。
- 原文未提及具体药物剂量、给药途径、频次或目标值。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:前瞻性、随机、开放标签试验,纳入152例患者(继续组75例,停药组77例),来自7国20家大型转诊医院。
- 人群特征:平均年龄62岁(SD 12),女性68例(45%),平均BMI 33 kg/m2(SD 8),糖尿病79例(52%)。
- 干预与对照:继续 vs 停用RAS抑制剂(ACEI或ARB)。
- 主要终点:全球排名评分中位排名继续组73(IQR 40-110) vs 停药组81(IQR 38-117),β系数8(95%CI -13至29),无显著差异。
- 关键次要终点:ICU入住或有创机械通气率继续组16/75(21%) vs 停药组14/77(18%);病死率继续组11/75(15%) vs 停药组10/77(13%)。
证据类型、等级与局限
- 证据类型:前瞻性、随机、开放标签试验(RCT)。
- 证据等级或推荐强度:原文未提及正式证据分级。
- 局限:样本量小(152例),开放标签设计,主要终点为复合排名评分,随访期间未提及长期结局。
对床旁实践的改变
- 对于COVID-19住院且既往使用RAS抑制剂的患者,急诊/ICU医生可继续使用RAS抑制剂,无需因COVID-19住院而常规停药。
- 继续用药不增加ICU入住、机械通气、死亡或不良事件风险,但需根据个体情况评估禁忌证。
- 不适用于对继续或停用RAS抑制剂有禁忌的患者。
- 常见陷阱:不应将本研究结果外推至非COVID-19住院患者或RAS抑制剂新启动的患者。
指南或共识出处
- REPLACE COVID trial(NCT04338009),发表于Lancet Respiratory Medicine。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Biological considerations suggest that renin-angiotensin system inhibitors might influence the severity of COVID-19. We aimed to evaluate whether continuing versus discontinuing renin-angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) affects outcomes in patients admitted to hospital with COVID-19.
METHODS: The REPLACE COVID trial was a prospective, randomised, open-label trial done at 20 large referral hospitals in seven countries worldwide. Eligible participants were aged 18 years and older who were admitted to hospital with COVID-19 and were receiving a renin-angiotensin system inhibitor before admission. Individuals with contraindications to continuation or discontinuation of renin-angiotensin system inhibitor therapy were excluded. Participants were randomly assigned (1:1) to continuation or discontinuation of their renin-angiotensin system inhibitor using permuted block randomisation, with allocation concealed using a secure web-based randomisation system. The primary outcome was a global rank score in which participants were ranked across four hierarchical tiers incorporating time to death, duration of mechanical ventilation, time on renal replacement or vasopressor therapy, and multiorgan dysfunction during the hospitalisation. Primary analyses were done in the intention-to-treat population. The REPLACE COVID trial is registered with ClinicalTrials.gov, NCT04338009.
FINDINGS: Between March 31 and Aug 20, 2020, 152 participants were enrolled and randomly assigned to either continue or discontinue renin-angiotensin system inhibitor therapy (continuation group n=75; discontinuation group n=77). Mean age of participants was 62 years (SD 12), 68 (45%) were female, mean body-mass index was 33 kg/m2 (SD 8), and 79 (52%) had diabetes. Compared with discontinuation of renin-angiotensin system inhibitors, continuation had no effect on the global rank score (median rank 73 [IQR 40-110] for continuation vs 81 [38-117] for discontinuation; β-coefficient 8 [95% CI -13 to 29]). There were 16 (21%) of 75 participants in the continuation arm versus 14 (18%) of 77 in the discontinuation arm who required intensive care unit admission or invasive mechanical ventilation, and 11 (15%) of 75 participants in the continuation group versus ten (13%) of 77 in the discontinuation group died. 29 (39%) participants in the continuation group and 28 (36%) participants in the discontinuation group had at least one adverse event (χ2 test of adverse events between treatment groups p=0·77). There was no difference in blood pressure, serum potassium, or creatinine during follow-up across the two groups.
INTERPRETATION: Consistent with international society recommendations, renin-angiotensin system inhibitors can be safely continued in patients admitted to hospital with COVID-19.
FUNDING: REPLACE COVID Investigators, REPLACE COVID Trial Social Fundraising Campaign, and FastGrants.
参考来源
- Cohen JB, Hanff TC, William P, et al. Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respir Med. 2021. PMID: 33422263. doi:10.1016/S2213-2600(20)30558-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。